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Abstract
The alternative splicing of the tau gene,MAPT, generates six protein isoforms in the adult human central nervous system (CNS).
Tau splicing is developmentally regulated and dysregulated in disease. Mutations in MAPT that alter tau splicing cause
frontotemporal dementia (FTD) with tau pathology, providing evidence for a causal link between altered tau splicing and
disease. The use of induced pluripotent stem cell (iPSC)-derived neurons has revolutionized the way we model neurological
disease in vitro. However, as most tau mutations are located within or around the alternatively spliced exon 10, it is important
that iPSC–neurons splice tau appropriately in order to be used as disease models. To address this issue, we analyzed the
expression and splicing of tau in iPSC-derived cortical neurons from control patients and FTD patients with the 10 + 16 intronic
mutation inMAPT. We show that control neurons only express the fetal tau isoform (0N3R), even at extended time points of 100
days in vitro. Neurons from FTD patients with the 10 + 16 mutation in MAPT express both 0N3R and 0N4R tau isoforms,
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demonstrating that this mutation overrides the developmental regulation of exon 10 inclusion in our in vitromodel. Further, at
extended time points of 365 days in vitro, we observe a switch in tau splicing to include six tau isoforms as seen in the adult
humanCNS. Our results demonstrate the importance of neuronalmaturity for use in in vitromodeling andprovide a system that
will be important for understanding the functional consequences of altered tau splicing.
Introduction
Hyperphosphorylated, insoluble aggregates of the microtubule-
associated protein tau are a pathological hallmark of a range of
clinically diverse disorders termed the tauopathies, which in-
clude Alzheimer’s disease (AD), progressive supranuclear palsy
(PSP) and corticobasal degeneration (CBD) (1). The link between
tau and neurodegeneration was conﬁrmed with the discovery
of mutations in the tau gene, MAPT, that cause frontotemporal
dementia (FTD) with tau pathology (2,3). These mutations either
alter the coding sequence of tau or the alternative splicing of
MAPT. In the adult human brain, alternative splicing of MAPT
generates six protein isoforms of tau, characterized by 0, 1 or 2
N-terminal inserts (coded by exons 2 and 3), and 3 or 4 C-terminal
inserts, the additional insert coded for by exon 10 (4–6). Exon 3 is
never included independently of exon 2, and therefore, six pro-
tein isoforms are generated: 0N3R, 0N4R, 1N3R, 1N4R, 2N3R and
2N4R (4,7). Tau splicing is developmentally regulated: only
0N3R tau is expressed in fetal stages, but all six isoforms are ex-
pressed in the adult central nervous system (CNS) with 3R and 4R
tau being present in equal amounts in normal conditions (6). 1N
tau isoforms account for 54% of total tau in the adult human
brain, 0N tau isoforms account for 37% of total tau and 2N tau iso-
forms are the least abundant, accounting for only 9% of total tau
proteins (7,8).
Proper tau splicing appears to be critical for neuronal health.
A subset of FTD-linked MAPT mutations alter the splicing of tau
exon 10, generally favoring an increase in exon 10 inclusion and
increased expression of 4R tau isoforms, thereby disrupting the
3R:4R tau ratio. Two common haplotypes exist at the MAPT
locus, H1 and H2, and H1 is associated with increased risk of
the 4R tauopathies PSP and CBD. Functional dissection of MAPT
haplotypes has shown that they can affect MAPT splicing at
exons 2, 3 and 10 (9–12). In spite of this wealth of evidence sup-
porting a role for altered tau splicing in disease pathogenesis,
themolecularmechanisms linking tau splicing to disease remain
poorly understood, in part due to the lack of in vitro models that
recapitulate the diversity of tau isoforms seen in the adult
human CNS.
The use of induced pluripotent stem cells (iPSC) differentiated
into neurons has quickly become awidely chosenmethod to gen-
erate physiologically relevant models of neurological diseases,
including dementia (13). Stem cells can be reliably differentiated
into cortical glutamatergic neurons, the main tangle-bearing
neurons in FTD (14). However, one potential limitation of using
this approach to model tauopathy is that the neurons are at
early stages of development; it remains to be seen if they recapitu-
late the tau splicing patterns seen in the adult humanCNS. This is
critical since many coding mutations in MAPT are located within
the alternatively spliced exon 10. It is necessary that neurons gen-
erated frompatientswithmutations in exon 10 express 4R tau iso-
forms in order for the model to express the mutant protein (2).
In the present study, we characterized tau expression, spli-
cing and phosphorylation in control cortical neurons and neu-
rons derived from FTD patients with the 10 + 16 splice-site
mutation in MAPT. The 10 + 16 mutation destabilizes a stem
loop structure in intron 10 leading to a 2–6-fold increase of exon
10-containing mRNA in patients (15,16). We show that control
neurons express mainly 0N3R tau, even at extended time points
of up to 100 days in vitro. This has important implications for dis-
ease modeling, as mutations within exon 10 of tau would not be
expressed in this in vitro system. In contrast, FTDneurons express
both 0N3R and 0N4R tau isoforms over the same time course,
demonstrating that the 10 + 16 mutation can override the devel-
opmental regulation of tau splicing. Finally, aging our control and
FTD neuronal cultures to 1 year in vitro results in a switch from
only 0N3R tau expression to expression of a diverse complement
of tau isoforms. Together, our data show that the developmental
regulation of tau splicing is faithfully recapitulated during in vitro
corticogenesis, and this is disrupted by FTD-causing splice-site
mutations in MAPT.
Results
iPSC and cortical neurons from patients with the 10 + 16
mutation in MAPT
Fibroblasts from two FTD patients with the 10 + 16 mutation in
MAPT were reprogrammed into iPSC using retrovirus-mediated
introduction of cMyc, Klf4, Oct4 and Sox2 as described previously
(17). Resulting iPSC clones expressed the stem cell markers Oct4,
Tra1-81 and SSEA4 and exhibited a normal karyotype (Fig. 1A).
FTD and age-matched control iPSC were differentiated into cor-
tical neurons by dual SMAD inhibition followed by an extended
period of in vitro neurogenesis (14). Cortical precursor rosettes,
positive for the early forebrainmarkers Pax6 andOtx1/2, were ob-
tained by Day 15 of differentiation. By Day 80, neurons positive
for deep-layer markers (Tbr1) and upper-layer markers (Satb2)
were present in culture (Fig. 1B). Tau haplotype status of each
cell linewas determinedusing a previously described polymerase
chain reaction (PCR) assay, which allows assignment of H1/H2
based in a 238 bp deletion found on the H2 background (18). All
three control lines used in this study were H1/H1 homozygous
(Fig. 1C). The two patients were H1/H1 homozygous (Patient 1)
and H1/H2 heterozygous (Patient 2).
iPSC-derived neurons express 0N3R tau, which
is phosphorylated at multiple epitopes
As tau splicing is developmentally regulated, we set out to inves-
tigate the temporal regulation of tau expression and splicing dur-
ing in vitro corticogenesis. Control iPSC and human embryonic
stem cell (hESC) were differentiated into cortical neurons, and
we examined tau expression and splicing using reverse tran-
scriptase-polymerase chain reaction (RT-PCR) and western blot
at different time points during differentiation (Fig. 2). RT-PCR
using primers spanning exon 10 showed the presence of two
bands of equal intensity in the human brain, corresponding to
3R and 4R tau isoforms (i.e. +/− exon 10). In contrast, although
tau mRNA was readily detectable in neurons differentiated
from control iPSC as early as Day 20 of differentiation, only a sin-
gle band was observed following RT-PCR analysis, corresponding
to 3R tau isoforms (Fig. 2A). No 4R taumRNAwas observed evenat
the extended time points of 100 days of differentiation.
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This ﬁnding was conﬁrmed at the protein level by western
blot analysis (Fig. 2B). Tau protein was detectable as a single
band at low concentration from Day 30 of differentiation, and
the levels of tau increased dramatically between Days 20 and 30
of differentiation, which coincides with the appearance of post-
mitotic neurons during differentiation (Fig. 2Bi). Dephosphoryla-
tion by lambda phosphatase followed by comparison with a
recombinant tau ladder conﬁrmed that this band corresponds
to the 0N3R tau isoform, and thiswas also conﬁrmed by immuno-
blot with the 3R-speciﬁc antibody RD3 (Fig. 2Bii). The expression
of 0N3R tau was found consistently across all control lines used,
as determined by analysis of dephosphorylated lysates after 100
days in vitro (Fig. 2C). Tau is highly phosphorylated during devel-
opment, reﬂecting the plasticity required during neuronal devel-
opment and the requirement for a dynamicmicrotubule network
(5,19–21). Tau phosphorylation atmultiple epitopes was detected
in control neurons by western blot (Fig. 3A) including PHF1
(pS396/pS404) and AT270 (pT181), both of which are highly phos-
phorylated during development and in control brain biopsies
(22).
Immunoﬂuorescence revealed no overlap between tau and
Ki67, a marker of cells undergoing mitosis (Fig. 3B), indicating
that tau was expressed only in post-mitotic neurons and not in
dividing neural precursors. Co-staining for total and phospho
tau revealed that tau was present throughout the cell body and
axon, with phospho tau mainly in axons consistent with a role
for tau in microtubule remodeling during axonal outgrowth.
Tau splicing is altered in neurons with the 10 + 16
splice-site mutation in MAPT
A large number of mutations in tau that are linked to FTD are lo-
cated within exon 10. Our results with control neurons indicate
that it will be difﬁcult to model these mutations in iPSC-derived
neurons, as the exon containing the mutation would be spliced
out in 0N3R tau; therefore, no mutant protein would be present
in the neuronal culture. We chose instead to focus on the
10 + 16 splice-sitemutation, which destabilizes a stem loop in in-
tron 10 resulting in increased production of 4R isoforms (15). FTD
patientswith the 10 + 16mutation have an average age at onset of
50 years and cortical neuroﬁbrillary tangles composed mainly of
4R tau isoforms are observed at postmortem (23–25).
iPSCs from two FTD patients with the 10 + 16 mutation were
differentiated into cortical neurons. RT-PCR with exon spanning
primers revealed the presence of both 3R and 4R tau in neurons
with the 10 + 16 mutation (Fig. 4A). This was conﬁrmed by
Figure 1. iPSC and cortical neurons from patients with the 10 + 16 splicing mutation inMAPT. (A) iPSCs were generated from ﬁbroblasts taken from two patients with the
10 + 16 intronic mutation inMAPT. iPSC expressed the pluripotency markers Oct4, SSEA4 and Tra1-81 and exhibited a stable karyotype. (B) Control andMAPT iPSCs were
differentiated into cortical neurons by dual SMAD inhibition followed by an extended period of in vitro corticogenesis. By Day 20, neural precursor rosettes were present,
which were positive for the early forebrain markers Pax6 and Otx1/2. By Day 80, cells had adopted a neuronal morphology and expressed the deep-layer transcription
factor Tbr1 and the upper-layer transcription factor Satb2. (C) The MAPT haplotype status of each stem cell line used in this study was analyzed using a PCR assay
that detects a 238 bp deletion on the H2 background. The three control lines used in this study were homozygous for the H1 haplotype. The two FTD patients were
H1/H1 and H1/H2. Human gDNAs from H1/H1, H1/H2 and H2/H2 haplotypes are included as positive controls.
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western blot (Fig. 4B) where two bands immunoreactive for total
tau were detected. RT-PCR of control and 10 + 16 neurons at Day
100 of differentiation revealed a complete absence of 4R tau in
control cells but a robust expression of exon 10 containing tran-
scripts in FTD neurons (Fig. 4C). Dephosphorylation of whole cell
lysates from control and FTD neurons after 100 days of differen-
tiation revealed that these corresponded to 0N3R and 0N4R tau
isoform expression by FTD 10 + 16 cells (Fig. 4D). This demon-
strates that theMAPT 10 + 16 splicing mutation is able to override
the developmental regulation of tau exon 10 splicing in vitro. Tau
phosphorylation in FTD neurons was found at similar levels to
control neurons (Fig. 4E), with the exception that both expressed
isoforms (0N3R and 0N4R) were phosphorylated at the epitopes
examined.
Postnatal tau splicing is observed at extended time points
in vitro
iPSC neurons expressed only the 0N3R fetal tau isoform even
after 100 days in vitro. We have also demonstrated that the
10 + 16 intronic mutation in MAPT alters tau splicing, resulting
in the production of 0N4R tau and 0N3R. Although these cells pro-
vide a useful platform for studying the functional consequences
of tau mis-splicing, it is desirable to have a neuronal cell model
that expresses all six tau isoforms. To test the hypothesis that
neurons would express postnatal patterns of tau at postnatal
time points, we aged neurons in culture up to 365 days and ana-
lyzed them for tau expression and splicing. At Day 365 in vitro, we
observed a switch in tau splicing in control neurons from only 3R
isoforms to both 3R and 4R tau by RT-PCR (Fig. 5A). Dephosphor-
ylation and alignment with a recombinant tau ladder revealed
the presence of 0N3R, 0N4R, 1N3R and 1N4R tau isoforms in con-
trol cells, including both 3R and 4R variants, but still with a pre-
dominance of 0N3R (Fig. 5B). In 10 + 16 neurons, 0N3R, 0N4R,
1N3R and 1N4R were also expressed, but with an increased
amount of 4R tau isoforms relative to controls. We were unable
to observe 2N tau isoforms; however, these comprise only 9% of
total tau in the adult brain, so it is possible that their levels are
below the limit of detection in our analysis (7,8).
Discussion
Wehave shown that tau splicing in iPSC-derived cortical neurons
recapitulates tau expression and splicing patterns seen in human
brain development. In vitro corticogenesis from iPSC takes 100
days in vitro, during this time iPSC neurons express only the
0N3R (fetal) tau isoform. This has important implications for
the use of iPSC in disease modeling. It is tempting to select clin-
ically aggressive tau mutations such as P301S for in vitro model-
ing, which can have an extremely early-onset and therefore
maximize chance of observing a cellular phenotype (26). How-
ever, these mutations are located in exon 10 of the tau gene,
which is spliced out in 100-day cortical neuronal cultures, and
so the mutant protein would not be present. Our results are con-
sistent with previous reports suggesting gene expression proﬁles
of PSC-derived neurons cluster more closely with fetal rather
Figure 2. iPSC-derived cortical neurons express the fetal isoform of tau. Control iPSC and hESC were differentiated into cortical neurons, and RNA and protein were
extracted at the time points indicated for analysis of tau expression and splicing. (A) RT-PCR with exon spanning primers located in exons 9 and 12 showed that only
3R tau was present in control neurons derived from hESC and two iPSC lines at all the time points analyzed, whereas bands of equal intensity corresponding to 3R
and 4R tau were detectable in the adult human brain. (B) Lysates were dephosphorylated and separated by SDS-PAGE for comparison with recombinant tau ladder.
Recombinant tau isoforms separate in order of decreasing molecular weight as follows: 2N4R, 2N3R, 1N4R, 1N3R, 0N4R and 0N3R. Western blots to total tau (i) showed
a single band at all the time points analyzed, corresponding to 0N3R tau. This was conﬁrmed by labeling with the 3R-speciﬁc antibody, RD3 (ii). The amount of tau
present increased in a time-dependent manner. A representative image from hESC-derived neurons is shown. (C) Lysates from hESC and control iPSC-derived cortical
neurons were collected after 100 days of differentiation and separated by SDS-PAGE alongside recombinant tau ladder. The presence of a single band after probing for
total tau conﬁrmed only 0N3R tau is present at the protein level.
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than adult neurons (27). In contrast, expression of exon 10-con-
taining tau isoforms has been reported in iPSC-derived dopamin-
ergic andmixed neuronal populations between 4 and 10weeks of
differentiation (28,29). The differences observed between this
and our own ﬁndings could indicate neuronal subtype-speciﬁc
regulation of tau splicing. It is worth noting that in all cases,
the 3R:4R ratio was still reduced compared with that observed
in the adult human brain. Our results suggest that successful
use of iPSC to model MAPT mutations will rely on the selection
of mutations that are present in constitutively expressed exons.
Several reports have successfully used iPSC technology to
model tau mutations; however, these have either focused on
mutations located outside of the alternatively spliced exons
such as the A152T variant, or have used overexpression of adult
tau isoforms (30,31). A recent report described a novel tau variant,
K298E, that leads to an overproduction of 4R tau when a mini
gene containing this variant is transfected into neural stem
cells (32). In contrast, we demonstrate for the ﬁrst time in a
human, neuronal, in vitro system that the intronic 10 + 16
splice-site mutation in MAPT can override the developmental
regulation of endogenous MAPT splicing, leading to the produc-
tion of 3R and 4R tau even at the earliest stages of neuronal devel-
opment. This mutation alters the secondary structure of mRNA,
disrupting a stem loop structure and leading to increased
Figure 3.Tau is expressed in post-mitotic neurons and phosphorylated atmultiple epitopes. (A)Whole cell lysates were collected from control cortical neurons at the time
points indicated, and total and phospho tau levels were assessed by western blot. Western blots with phospho-speciﬁc tau antibodies to pT181 and pS396/S404 showed
that tau is phosphorylated atmultiple epitopes associated with high levels of tau phosphorylation during development. n = 3, independent cultures for one hESC and two
iPSC lines, representative images fromeach line are shown. (B) Immunoﬂuorescence of cortical neurons at Day 30 of differentiation showed that tauwas readily detectable
in neuronal cultures but did not co-localizewith Ki67, amarker of dividing cells, thus indicating tau is only expressed in post-mitotic neurons. Representative images from
Control 2 iPSC are shown.
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inclusion of exon 10 (15). It will be interesting to investigate
whether nonsynonymous and synonymous MAPT mutations
such as N296H andN296N, which alter tau splicing via disrupting
the recruitment of splicing factors, are able to override the devel-
opmental regulation of tau splicing in the sameway (33). It is also
interesting to speculate whether this mutation could lead to a
neurodevelopmental cellular phenotype in patients, which pre-
cedes disease onset by many years.
Our model will provide an in vitro system to understand the
functional differences between 3R and 4R tau and the conse-
quences of altered tau splicing. 4R tau isoforms bind microtu-
bules with higher afﬁnity than 3R tau (34,35), so alterations in
the 3R:4R ratio will affect the microtubule network and subse-
quently axonal transport. Indeed, 3R and 4R tau differentially
affect mitochondrial transport within the neuron, and in-
creased 4R tau results in increased localization of mitochondria
Figure 4. Tau splicing is altered in neurons from patients with the 10 + 16mutation inMAPT. iPSCs from two FTD patients with the 10 + 16 intronicmutation inMAPTwere
differentiated into cortical neurons, and RNA and protein were extracted at the time points indicated for the analysis of tau expression and splicing. (A) RT-PCR revealed
the expression of both 3R and 4R tau isoforms at all the time points analyzed. (B)Western blots ofwhole cell lysates to total tau revealed the presence of two protein bands
throughout differentiation. (C) RT-PCR of control and 10 + 16 neurons at 100 days of differentiation conﬁrmed a robust 4R tau expression in 10 + 16 cells and a complete
absence of 4R in control neurons. (D) Whole cell lysates were collected after 100 days of differentiation and analyzed for tau isoform expression at the protein level by
comparison with control cell lysates and recombinant tau ladder. Recombinant tau isoforms separate in order of decreasing molecular weight as follows: 2N4R, 2N3R,
1N4R, 1N3R, 0N4R and 0N3R. Dephosphorylation of protein extracts by lambda phosphatase revealed a single band in control neurons but two protein bands in FTD
10 + 16 patient cells, corresponding to the expression of 0N3R and 0N4R tau isoforms. (E) Phosphorylation status of tau was assessed in control and FTD neurons after
100 days of differentiation. No hyperphosphorylation of tau in FTD cells was observed; however, both 0N3R and 0N4R isoforms were phosphorylated at the epitopes
examined. n = 3, independent cultures from each patient, representative images shown.
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to the cell bodyanda reduction ofmitochondria in the axon (36). It
is important to note that many studies have relied on over-
expression of tau to investigate its role in axonal transport;
however, this can lead to clogging of axons and dramatic
reorganization of the neuronal cytoskeleton (37). It is, therefore,
crucial to study functional differences between tau isoforms in a
systemwith physiological expression levels of 3R and 4R tau. Fur-
ther, as correcting aberrant tau splicing could be a possible thera-
peutic avenue for treatment of 4R tauopathy, our model would
provide a drug-screening platform to test novel therapies.
We observed a switch in tau splicing at time points that could
be considered postnatal. Although this is consistent with the dif-
ference in tau splicing observed in the fetal and postnatal brains,
it is not feasible to routinely age cell culture to 1 year formechan-
istic and drug discovery purposes. It is, therefore, necessary to
devise methods to accelerate the acquisition of mature tau spli-
cing. Several candidate splicing factors that could be involved
in the postnatal reprogramming of tau splicing exist, perhaps
most promising are the CUG-BP- and ETR-3-like factors and
muscleblind-like proteins; both of which are known to act on
MAPT and have been shown to synergistically coordinate splicing
events involved in postnatal heart remodeling (38–40). It is of note
that 3D-based cell culture systems have demonstrated increased
4R tau expression when compared with 2D cell cultures (41). It
will also be interesting and important to verify if other alternative
splicing events associated with postnatal neuronal development
occur in our system, such as ﬂip/ﬂop splicing of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunits
and alternative usage of exon 18 of sodium channel 8A (42,43).
In summary, our study demonstrates the potential of iPSC
technology to be useful in modeling FTD caused by mutations
inMAPT, but also some of the obstacles with respect to develop-
mental regulation of tau expression. Ongoing studies aim to ac-
celerate neuronal differentiation and acquisition of mature tau
splice variants in a time framemore suitable to diseasemodeling;
nonetheless, we provide an in vitro model suitable for under-
standing disrupted MAPT splicing in FTD.
Materials and Methods
Generation of ﬁbroblast lines
Primary ﬁbroblast lines were generated from 4 mm skin punch
biopsies, which were obtained under informed consent. Ethical
permission for this study was obtained from the National Hos-
pital for Neurology and Neurosurgery and the Institute of Neur-
ology joint research ethics committee (study reference 09/
H0716/64). The generation and characterization of ﬁbroblast
lines have been previously described (44).
Reprogramming of ﬁbroblasts into induced pluripotent
stem cells
Fibroblasts were reprogrammed into iPSC by viral transduction of
cMyc, Oct4, Klf4 and Sox2 as described previously (17). Brieﬂy,
ﬁbroblasts were transduced with viral particles and maintained
on a mouse embryonic ﬁbroblast feeder layer in hESC medium
[KO-DMEM, 20% knockout serum replacement, 2 m l-glutamine,
1 × nonessential aminoacids, 50 μM2-mercaptoethanol, 50 Uml−1
penicillin, 50 μg ml−1 streptomycin (all from Invitrogen), and20 ng
ml−1 FGF2 (Peprotech)] until colonies with iPSC morphology were
observed. Colonies with iPSC morphology were mechanically
picked and clonally expanded for further characterization. Karyo-
typing of iPSC was performed by Cell Guidance Systems, UK.
Pluripotent stem cells (PSCs) were subsequently cultured under
feeder-free conditions onGeltrex in Essential 8media (Invitrogen).
Cultures were fed daily and passaged every 5–7 days. The hESC
line Shef 6 was obtained from the UK Stem Cell Bank, and control
iPSCs, also generated using retroviral transduction, were obtained
from the laboratory of Dr Tilo Kunath.
MAPT haplotype analysis
MAPT haplotype was determined using a PCR assay to detect the
presence of a 238 bp deletion on the H2 background between
exons 9 and 10 (18). Genomic DNA was extracted from iPSC
Figure 5. Tau splicing in vitro at extended time points recapitulates development. To investigate whether neurons would express a postnatal pattern of tau splicing at
postnatal time points in culture, cells were aged to extended time points up to 365 days. (A) RT-PCR showed a robust expression of 3R and 4R tau in both control and
10 + 16 neurons after 365 days of culture. (B) Western blotting of lysates after dephosphorylation with lambda phosphatase revealed cortical neurons expressed
multiple tau isoforms after 365 days in culture. Recombinant tau isoforms separate in order of decreasing molecular weight as follows: 2N4R, 2N3R, 1N4R, 1N3R,
0N4R and 0N3R. Control neurons expressed 0N3R, 0N4R, 1N3R and 1N4R tau. 10 + 16 neurons expressed the same complement of tau isoforms but with higher levels
of 4R tau. n = 3, independent cultures for two control iPSC lines and one patient iPSC line.
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using phenol–chloroform extraction. Cells were lysed [110 m
Tris pH 8, 50 m ethylenediaminetetraacetic acid (EDTA),
100 m NaCl, 0.5% sodium dodecyl sulfate (SDS) with 0.5 mg/ml
of proteinase K (Qiagen)] overnight at 37°C for complete protein
digestion. DNA was extracted by adding an equal volume of
phenol:chloroform:isoamyl alcohol (25:24:1) (#77617, Sigma) to
lysates followed by precipitation using 100% ethanol and 1/30
of the volume of 3 M sodium acetate. DNA was precipitated for
1 h at −20°C and centrifuged at 13 000g(av) for 15 min. DNA was
washed three times in 70% ethanol prior to dissolving in TE buffer
and stored at 4°C. The PCRwas performedwith genomic DNA at a
ﬁnal volume of 25 μL under the following conditions: 94°C for
2 min, 35 cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 1 min
and a ﬁnal step of 10 min at 72°C. The concentrations of the for-
ward and reverse primers were at 10 m, and the sequences for
both the primers were as follows: forward 5′ GGAAGACGTTCTC
ACTGATCTG and reverse 5′ AGGAGTCTGGCTTCAGTCTCTC. All
PCRs were performed with GoTaq® Hot Start Colorless Master
Mix, and theywere run in a 1.5% agarose gel with a 100 bp ladder.
Differentiation of iPSC into cortical neurons
PSCs were differentiated into cortical neurons using dual SMAD
inhibition followed by in vitro neurogenesis, as described previ-
ously (14,45). Brieﬂy, PSCs were grown to 100% conﬂuence before
themedia was changed to neural induction media [A 1:1 mixture
of N-2 and B-27-containing media supplemented with the SMAD
inhibitors dorsomorphin (1 μM) and SB431452 (10 μM Tocris). N-2
medium consists of DMEM/F-12 GlutaMAX, 1 × N-2, 5 μgml−1
insulin, 1 m l-glutamine, 100 μ nonessential amino acids, 100
M 2-mercaptoethanol, 50 U ml−1 penicillin and 50 mgml−1 strep-
tomycin. B-27medium consists of Neurobasal, 1 × B-27, 200 m l-
glutamine, 50 U ml−1 penicillin and 50 mg ml−1 streptomycin (all
from Invitrogen).] Media was changed daily for a 12-day period
during which time PSCs were converted to a neuroepithelial
layer. At Day 12, cells were replated onto laminin-coated plates
using dispase (Invitrogen), and cells were fed every 2 days with
neural maintenance media (A 1:1 mix of N2 and B27, as de-
scribed). Cells were replated with accutase (Invitrogen) once a
substantial amount of neurogenesis has occurred (around Day
28) and then replated for the ﬁnal time at Day 35 onto poly-
ornithine and laminin-coated plates (Sigma).
Western blotting
Cells were lysed in 10 m Tris, pH 7.4, 100 m NaCl, 1 m EDTA,
1 m EGTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxy-
cholate, plus protease and phosphatase inhibitors (Roche) for 1 h
at 4°C. Proteins were separated on SDS-polyacrylamide gel elec-
trophoresis (PAGE) BisTris gels (NuPAGE Novex, 10% or 4–12%, In-
vitrogen) and subsequently transferred onto nitrocellulose
membranes. Membraneswere blocked in phosphate-buffered sa-
line containing 3%milk (PBS-M) for 1 h at room temperature (RT).
Membranes were incubated in primary antibody in PBS-M over-
night at 4°C. Blots were developed with IRDye 800-conjugated
goat anti-rabbit (Rockland, Inc.) or IRDye 680-conjugated goat
anti-mouse (Molecular Probes, Eugene, OR, USA) and visualized
using an Odyssey Infrared Imaging System (Li-Cor Biosciences).
For analysis of tau isoforms, samples were dephosphorylated
prior to electrophoresis using lambda protein phosphatase as de-
scribed previously (46) and separated by SDS-PAGE alongside a
recombinant tau ladder (Sigma).
Immunoﬂuorescence
Cellswere grown in eight-well chamber slides (Ibidi) for immuno-
ﬂuorescence. Cells were ﬁxed in 4% PFA for 20 min at RT, washed
with PBS and blocked in 5% goat serum and 0.1% Triton X-100 in
PBS. Cells were incubated in primary antibody overnight at 4°C
(Table 1). Cells were then incubated with Alexa Fluor 488 and
568 antibodies (Invitrogen, 1:500) for 1 h at RT, and nuclei were
stained using 4′,6-diamidino-2-phenylindole. Images were ob-
tained using a Zeiss LSM microscope.
Reverse transcriptase-polymerase chain reaction
To determine the presence of tau isoforms +/− exon 10, semi-
quantitative RT-PCR was performed using primers located in
exons 9 and 13 of MAPT, as described previously (47). Total RNA
was extracted from cells using Trizol (Life Technologies) accord-
ing to the manufacturer’s protocol. Reverse transcription was
performed with the SuperScript III ﬁrst strand kit (Invitrogen)
with oligo(dT) or an equimolar ratio of oligo(dT) and randomhex-
amers. Each reaction contained 0.5–2 μg of RNA in a total volume
of 20 μl. Reverse transcription conditions were as follows: incuba-
tion at 65°C for 5 min of RNA, random hexamers and 10 m
dNTPs followed by 1 min on ice. The cDNA synthesis Mix [10X
RT Buffer, 25mMMgCl2, 0.1MDTT, RNaseOUT (40 U), SuperScript
III RT (200U)] was then added and cDNA synthesiswas carried out
for 10 min at 25°C, 50 min at 50°C, and 5min at 85°C to terminate
the reaction. To detect MAPTmRNA +/− exon 10, cDNAwas amp-
liﬁed with primers located in exon 9 (5′ GTCAAGTCCAAGATCGG
CTC 3′) and exon 13 (5′ TGGTCTGTCTTGGCTTTGGC 3′). Glyceral-
dehyde 3-phosphate dehydrogenasewas ampliﬁed using the fol-
lowing primers: forward (5′CCATGGCACCGTCAAGGCTGA 3′) and
reverse (5′ GCCAGTAGAGGCAGGGATGAT 3′). Product ampliﬁca-
tion was obtained using Taq DNA polymerase with standard
Taq buffer (BioLabs). PCR products were separated on 1% agarose
gels and stained with GelRed (Biotium).
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